AGENDA

I. Welcome and Introductory Remarks

II. Guest Forum
A pharmaceutical representative from Amneal will offer testimony on carbidopa/levodopa extended-release capsule.

III. Annual Pipeline Continuing Education Program
The Pipeline Update will provide an overview of clinical and/or regulatory updates regarding select pharmaceutical pipeline agents in late-stage development.

IV. Vitrakvi (larotrectinib) New Drug Review
This overview is an evaluation of current medical literature and will provide a brief overview of the place in therapy of this agent.

V. MHDL Update
The MHDL Overview will include new additions, changes in Prior Authorization (PA) status, and related attachment updates to be implemented with a recent publication rollout.

VI. DUR Operational Update
The DUR Operational Overview will include statistics associated with Prior Authorization (PA) review and PA response, and Call Center metrics.

VII. MassHealth Update
The MassHealth Update is a brief summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.

VIII. Antiparkinsonian Agents Quality Assurance Analysis
This overview is an evaluation of current medical literature and will provide a brief overview of new guideline recommendations in this disease state.
(time permitting)
The Massachusetts Commission for the Deaf and Hard of Hearing will assist with arrangements for a sign language interpreter. The Commission may be reached at (617) 740-1600 VOICE and (617) 740-1700 TTY.

Next DUR Board (open meeting): June 12, 2019